Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Ader (lopinavir/ritonavir plus interferon), 2021 NCT04315948

lopinavir/ritonavir plus interferon ß-1a (n=145) vs. standard of care (n=148)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Lopinavir/ritonavir plus interferon beta-1a
Standard of care plus lopinavir/ritonavir (400 mg lopinavir and 100 mg ritonavir orally twice on day for 14 days) plus IFN-ß-1a (44 µg of subcutaneous IFN-ß-1a on days 1, 3, and 6).

Control treatment

Standard of care

Supportive treatments corticosteroids, anticoagulants or immunomodulatory agents were allowed except antivirals.

Patients

COVID 19 hospitalized

Method

Open-label.

30 sites in France and 2 in Luxembourg.

The 7-point ordinal scale was defined as: 1. Not hospitalized, no limitation on activities; 2. Not hospitalized, limitation on activities; 3. Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalized, on invasive mechanical ventilation or ECMO; 7. Death.

Remark

Add-on trial to Solidarity.